GRI Bio Inc. (GRI)
NASDAQ: GRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GRI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.45M
- P/E (TTM)
- 0.05
- EPS (TTM)
- $20.57
- Dividend yield
- None
- 52-week range
- 1.09 – 64.12
- Day range
- 1.12 – 1.25
- Volume / Avg
- 25.07K / 218.31K
- Beta
- —
- Shares outstanding
- 2.19M
52-week range
GRI stock today
GRI Bio (GRI) closed at $1.12 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 25.07K shares changing hands, about 11% of the average daily volume. At this level, GRI sits near the bottom of its 52-week range of $1.09 to $64.12: 98.3% below the high and 2.8% above the low.
GRI Bio trades at 0.1x its trailing twelve-month earnings per share of $20.57.
Summary generated from market data by MetaCap's automated system. Methodology
About GRI Bio
Company profileGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Employees
- 3
- IPO year
- 2021
- Website
- gribio.com
Financial highlights
Full financialsGRI Bio reported a net loss of $12.0 million, compared with a loss of $8.2 million a year earlier. Diluted earnings per share came in at -$121.80.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Growth | — | — | — | — | -100.00% |
| Net income | $-11.96M | $-8.21M | $-13.04M | $-3.22M | $-9.30M |
| EPS (diluted) | $-121.80 | $-1,545.55 | $-5,018.09 | $-24.95 | $-1.42 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$18.50+1551.79%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.69 vs $-0.84
- Surprise
- +17.86%
GRI Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RDHLRedhill Biopharma Ltd. ADR | 0.281 | -13.08% | $2.50M | vs GRI |
| DRMADermata Therapeutics Inc. | 0.5095 | -4.23% | $2.51M | vs GRI |
| ONCOOnconetix Inc. | 2.89 | -8.54% | $2.37M | vs GRI |
| HCWBHCW Biologics Inc. | 0.7491 | +1.90% | $2.35M | vs GRI |
| ERNAErnexa Therapeutics Inc. | 1.36 | -16.56% | $2.30M | vs GRI |
| MBIOMustang Bio Inc. | 0.3541 | -4.30% | $2.69M | vs GRI |
| TRAWTraws Pharma Inc. | 0.175 | -23.91% | $2.69M | vs GRI |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.2449 | +15.03% | $2.19M | vs GRI |
Indexes, lists and sector
GRI Bio stock FAQ
What is GRI Bio's stock price today?
GRI last traded at $1.12 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
What is GRI's P/E ratio?
GRI trades at a trailing P/E ratio of 0.05.
What is the GRI 52-week high?
The 52-week high for GRI is $64.12 and the 52-week low is $1.09. The stock is currently 98.3% below its high.